Position in SYRE
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$33,621,488
+$27,063,854 QoQ
Shares Held
666,564
+233.0% QoQ
Ownership
0.768%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SYRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Capital World Investors holds $23,534,298,325 across 32 Biotechnology names. SYRE ranks #23 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
25,368,124 | $11,327,882,090 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
10,802,348 | $3,574,172,882 | |
| 3 | ARGX |
Argenx SE
|
2,256,216 | $1,647,601,734 | |
| 4 | IONS |
Ionis Pharmaceuticals Inc
|
21,186,369 | $1,590,884,448 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,419,000 | $1,096,376,160 | |
| 6 | MRNA |
Moderna, Inc.
|
18,697,694 | $949,842,855 | |
| 7 | JAZZ |
Jazz Pharmaceuticals plc
|
2,673,376 | $505,401,732 | |
| 8 | ONC |
BeOne Medicines Ltd.
|
1,622,687 | $481,889,358 |
All Filings in SYRE
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $33,621,488 | 666,564 | Shares | Defined | 2026-05-13 | |
| 2025-12-31 | $6,557,634 | 200,172 | Shares | Defined | 2026-02-11 | |
| 2025-09-30 | $3,354,882 | 200,172 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $5,251,086 | 350,774 | Shares | Defined | 2025-08-13 | |
| 2025-03-31 | $5,659,738 | 350,774 | Shares | Defined | 2025-05-12 | |
| 2024-12-31 | $8,813,179 | 378,573 | Shares | Defined | 2025-02-13 | |
| No filing history on record for this holder in this stock. | ||||||